Interestingly, though hyperglycemia has been an anticipated adverse event when using agents that inhibit the PI3K pathway due to its influence on cellular metabolism and insulin/glucose regulation, NVP-BKM120 is the only inhibitor in clinical trials that has encountered clinically relevant elevations in plasma glucose. The gene discussed is PIK3CA; the disease is Hyperglycemia.